Seeking Alpha

Cornerstone Therapeutics (CRTX) +9.3% premarket after announcing that the FDA has accepted a new...

Cornerstone Therapeutics (CRTX) +9.3% premarket after announcing that the FDA has accepted a new drug application for CRTX 080, its product candidate for the treatment of hyponatremia.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector